Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

Background Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation. Objective This study investigates the cost-effectiveness of betibeglogene autotemcel (‘beti-cel’; LentiGlobin for β-thalasse...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Anuraag R. Kansal, Odette S. Reifsnider, Sarah B. Brand, Neil Hawkins, Anna Coughlan, Shujun Li, Lael Cragin, Clark Paramore, Andrew C. Dietz, J. Jaime Caro
Format: article
Langue:EN
Publié: Taylor & Francis Group 2021
Sujets:
Accès en ligne:https://doaj.org/article/d6cb861054544eae9f3fd0425864a1ec
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!